Food Lipids: Chemistry, Nutrition, and Biotechnology

5. J. W. Gofman, F. Lindgren, H. Elliott, W. Mantz, J. Hewitt, B. Strisower, V. Herring,
and T. P. Lyon. The role of lipids and lipoproteins in atherosclerosis. Science 111:166
(1950).
6. A. Keys. Atherosclerosis: A problem in new public health. J. Mt. Sinai Hosp. 20:118
(1953).
7. K. Berg. A new serum type system in man: The Lp(a) system. Acta. Pathol. Microbiol.
Scand. 59:369 (1963).
8. G. M. Kostner, P. Avogaro, G. Cazzolato, E. Marth, G. Bittolo-Bon, and G. B. Quinci.
Liproprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis 38:51 (1981).
9. G. G. Rhoades, G. Dahlen, K. Berg, N. E. Morton, and A. L. Dannenberg. Lp(a)
lipoprotein as a risk factor for myocardial infarction. J. Am. Med. Assoc. 256:2540
(1986).
10. J. Loscalzo. Lipoprotein(a): A unique risk factor for atherothrombotic disease. Arteriosclerosis
10:672 (1990).
11. J. M. Edelberg and S. V. Pizzo. Lipoprotein(a): The link between impaired fibrinolysis
and atherosclerosis. Fibrinolysis 5:135 (1991).
12. S. A. Brown, J. Morrisett, J. R. Patch, R. Reeves, A. M. Gotto, Jr., and W. Patsch.
Influence of short-term dietary cholesterol and fat on human plasma Lp(a) and LDL
levels. J. Lipid Res. 32:1281 (1991).
13. H. G. Fieseler, V. W. Armstrong, E. Wieland, J. Thiery, E. Schütz, A. K. Walli, and D.
Seidel. Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase
inhibitor provastatin: Results of a 2-year investigation. Clin. Chim. Acta 204:291
(1991).
14. R. M. Krauss, F. T. Lindgren, and R. M. Ray. Interrelationships among subgroups of
serum lipoproteins in normal human subjects. Clin. Chim. Acta 104:275 (1980).
15. T. A. Musliner and R. M. Krauss. Lipoprotein subspecies and risk of coronary disease.
Clin. Chem. 34:B78 (1988).
16. M. A. Austin, J. L. Breslow, C. H. Hennekens, J. E. Buring, W. C. Willett, and R. M.
Krauss. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J.
Am. Med. Assoc. 260:1917 (1988).
17. P. S. Roheim and B. F. Asztalos. Clinical significance of lipoprotein size and risk of
coronary atherosclerosis. Clin. Chem. 41:147 (1995).
18. I. Rajman, S. Maxwell, R. Cramb, and M. Kendall. Particle size: The key to atherogenic
lipoprotein? Q. J. Med. 87:709 (1994).
19. M. A. Austin. Genetic epidemiology of dyslipidaemia and atherosclerosis. Ann. Med.
28:459 (1996).
20. S. Stender and D. B. Zilversmit. Transfer of plasma lipoprotein components and of
plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant
of plasma lipoprotein influx. Arteriosclerosis 1:38 (1981).
21. B. G. Nordestgaard and D. B. Zilversmit. Large lipoproteins are excluded from the
arterial wall in diabetic cholesterol-fed rabbits. J. Lipid Res. 29:1491 (1988).
22. D. Kritchevsky. Variation in serum cholesterol levels. In: Nutrition Update (J. Weininger
and G. M. Briggs, eds.). John Wiley and Sons, New York, 1985, p. 91.
23. D. J. Gordon, J. Hyde, D. C. Trost, F. S. Whaley, P. J. Hannan, D. R. Jacobs, and L.
G. Ekelund. Cyclic seasonal variation in plasma lipid and lipoprotein levels: The lipid
research clinics coronary primary prevention trial placebo group. J. Clin. Epidemiol.
41:679 (1988).
24. D. Robinson, E. A. Bevan, S. Hinohara, and T. Takahashi. Seasonal variation in serum
cholesterol levels—evidence from the UK and Japan. Atherosclerosis 95:15 (1992).
25. D. M. Hegsted and R. J. Nicolosi. Individual variation in serum cholesterol levels.
Proc. Natl. Acad. Sci. USA 84:6259 (1987).
Copyright 2002 by Marcel Dekker, Inc. All Rights Reserved.